1. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence;Hanafiah K Mohd;Hepatology,2013
2. Evolving epidemiology of hepatitis C virus;D Lavanchy;Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases,2011
3. World Health Organization. Hepatitis C: fact sheet Geneva, Switzerland [updated April 2014; cited 2015 02/02]. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/.
4. Centers for Disease Control and Prevention. Hepatitis C Atlanta, USA [updated August 1, 2013; cited 2015 02/02]. Available from: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/hepatitis-c.
5. A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection from The Liver Meeting 2013: The 64th Annual Meeting of the American Association for the Study of Liver DiseasesNovember 1–5, 2013 • Washington DCSpecial Reporting on:• Simeprevir plus Sofosbuvir with or without Ribavirin Produces High SVR Rates in Genotype 1 HCV Infection• Novel Interferon- and Ribavirin-Free Regimen Results in SVR12 Rates of Over 90% in HCV Genotype 1b Infection• Studies Confirm Efficacy of Adjunctive Simeprevir in Difficult-to-Treat HCV Genotype 1 Subpopulations• All-Oral Therapy with Sofosbuvir Plus Ribavirin Produces High SVR Rates in Patients Coinfected with HCV and HIV• Faldaprevir Combined with Pegylated Interferon and Ribavirin Demonstrates High Efficacy in DifficuIt-to-Treat HCV Infection• Once Daily Sofosbuvir/Ledipasvir Combination Elicits Rapid Decline in HCV RNA Gastroenterology & Hepatology. 2014;10(1 Suppl 1):1–19.